| Expression pattern: |
DS |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Contributes to a five-circRNA plasma extracellular vesicle signature that stratifies mCRPC patients receiving first-line abiraterone into high-risk and low-risk groups and predicts overall survival. |
| Molecular mechanism: |
Prognostic plasma extracellular vesicle circRNA biomarker signature associated with abiraterone resistance; biological mechanism not elucidated. |
| Biological pathway or process: |
drug resistance (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNase R Treatment; circRNA-seq; RT-qPCR; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Included in a five-circRNA signature that independently predicts overall survival in mCRPC patients receiving first-line abiraterone; positive coefficient in the risk score indicates higher expression contributes to higher risk score. |
| Description: |
circFAM13A is one of five plasma extracellular vesicle circRNAs selected for an mCRPC prognostic signature in patients receiving first-line abiraterone. Its positive coefficient in the risk-score formula suggests that higher circFAM13A expression contributes to a higher-risk signature, which is associated with shorter overall survival. |
| Confidence score: |
0.6759 |